公开(公告)号：US20210355220A1

公开(公告)日：2021-11-18

申请号：US17278261

申请日：2019-09-20

Applicant: Tikcro Technologies Ltd. ,  Yeda Research and Development Co. Ltd.

Inventor： Ami Navon ,  Aviv Boim ,  Ariel Stanhill ,  Leehee Weinberger ,  Yuval Avnir

IPC: C07K16/28

Abstract: Disclosed herein are anti-CTLA-4 antibodies possessing superior binding and biological activities relative to ipibmumab and tremelimumab, pharmaceutical compositions comprising such. Also provided herein are therapeutic and diagnostic applications of such anti-CTLA-4 antibodies.

公开(公告)号：US20230132385A9

公开(公告)日：2023-04-27

申请号：US17278261

申请日：2019-09-20

Applicant: Tikcro Technologies Ltd. ,  Yeda Research and Development Co. Ltd.

Inventor： Ami Navon ,  Aviv Boim ,  Ariel Stanhill ,  Leehee Weinberger ,  Yuval Avnir

IPC: C07K16/28

Abstract: Disclosed herein are anti-CTLA-4 antibodies possessing superior binding and biological activities relative to ipibmumab and tremelimumab, pharmaceutical compositions comprising such. Also provided herein are therapeutic and diagnostic applications of such anti-CTLA-4 antibodies.